000131724 001__ 131724
000131724 005__ 20240229105009.0
000131724 0247_ $$2doi$$a10.1016/j.oraloncology.2017.11.015
000131724 0247_ $$2pmid$$apmid:29290288
000131724 0247_ $$2ISSN$$a1368-8375
000131724 0247_ $$2ISSN$$a1744-7895
000131724 0247_ $$2ISSN$$a1878-0601
000131724 0247_ $$2altmetric$$aaltmetric:31161998
000131724 037__ $$aDKFZ-2018-00030
000131724 041__ $$aeng
000131724 082__ $$a610
000131724 1001_ $$0P:(DE-He78)bbfe0ebad1e3b608bca2b49d4f86bd09$$aJansen, Lina$$b0$$eFirst author$$udkfz
000131724 245__ $$aDifferences in incidence and survival of oral cavity and pharyngeal cancers between Germany and the United States depend on the HPV-association of the cancer site.
000131724 260__ $$aAmsterdam [u.a.]$$bElsevier41102$$c2018
000131724 3367_ $$2DRIVER$$aarticle
000131724 3367_ $$2DataCite$$aOutput Types/Journal article
000131724 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1659952058_8496
000131724 3367_ $$2BibTeX$$aARTICLE
000131724 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000131724 3367_ $$00$$2EndNote$$aJournal Article
000131724 520__ $$aThe epidemiology of squamous cell oral cavity and pharyngeal cancers (OCPC) has changed rapidly during the last years, possibly due to an increase of human papilloma virus (HPV) positive tumors and successes in tobacco prevention. Here, we compare incidence and survival of OCPC by HPV-relation of the site in Germany and the United States (US).Age-standardized and age-specific incidence and 5-year relative survival was estimated using data from population-based cancer registries in Germany and the US Surveillance Epidemiology and End Results (SEER) 13 database. Incidence was estimated for each year between 1999 and 2013. Relative survival for 2002-2005, 2006-2009, and 2010-2013 was estimated using period analysis.The datasets included 52,787 and 48,861 cases with OCPC diagnosis between 1997 and 2013 in Germany and the US. Incidence was much higher in Germany compared to the US for HPV-unrelated OCPC and more recently also for HPV-related OCPC in women. Five-year relative survival differences between Germany and the US were small for HPV-unrelated OCPC. For HPV-related OCPC, men had higher survival in the US (62.1%) than in Germany (45.4%) in 2010-2013. These differences increased over time and were largest in younger patients and stage IV disease without metastasis. In contrast, women had comparable survival for HPV-related OCPC in both countries.Strong survival differences between Germany and the US were observed for HPV-related OCPC in men, which might be explained by differences in HPV-attributable proportions. Close monitoring of the epidemiology of OCPC in each country is needed.
000131724 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000131724 588__ $$aDataset connected to CrossRef, PubMed,
000131724 7001_ $$aButtmann-Schweiger, N.$$b1
000131724 7001_ $$aListl, S.$$b2
000131724 7001_ $$aRessing, M.$$b3
000131724 7001_ $$aHolleczek, B.$$b4
000131724 7001_ $$aKatalinic, A.$$b5
000131724 7001_ $$aLuttmann, S.$$b6
000131724 7001_ $$aKraywinkel, K.$$b7
000131724 7001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b8$$eLast author$$udkfz
000131724 7001_ $$0P:(DE-HGF)0$$aGroup, GEKID Cancer Survival Working$$b9$$eCollaboration author
000131724 773__ $$0PERI:(DE-600)2202218-1$$a10.1016/j.oraloncology.2017.11.015$$gVol. 76, p. 8 - 15$$p8 - 15$$tOral oncology / Supplement$$v76$$x1368-8375$$y2018
000131724 909CO $$ooai:inrepo02.dkfz.de:131724$$pVDB
000131724 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)bbfe0ebad1e3b608bca2b49d4f86bd09$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000131724 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000131724 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000131724 9141_ $$y2018
000131724 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000131724 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000131724 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000131724 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000131724 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000131724 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000131724 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000131724 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000131724 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000131724 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000131724 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000131724 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000131724 9201_ $$0I:(DE-He78)G110-20160331$$kG110$$lPräventive Onkologie$$x1
000131724 9201_ $$0I:(DE-He78)L101-20160331$$kL101$$lDKTK Heidelberg$$x2
000131724 980__ $$ajournal
000131724 980__ $$aVDB
000131724 980__ $$aI:(DE-He78)C070-20160331
000131724 980__ $$aI:(DE-He78)G110-20160331
000131724 980__ $$aI:(DE-He78)L101-20160331
000131724 980__ $$aUNRESTRICTED